Norbrook Presents API and Finished Products Portfolio at CPhI
Norbrook Laboratories will be showcasing its portfolio of APIs and its range of Norbrook Finished Product at CPhI Worldwide 2014.
Norbrook Laboratories will be showcasing its portfolio of APIs and its range of Norbrook Finished Product at CPhI Worldwide 2014. Norbrook’s exhibition stand is 6M99.
“Beyond Norbrook’s own-brand finished goods, we offer a range of contract manufacturing services. We offer process development from laboratory-scale, pilot-plant scale through to production-scale manufacture. We also offer a full complement of validation and technical services,” Professor James Haughey, the company’s director, said in a press release.
Norbrook specializes in the manufacture of APIs, including oxytetracycline HCL and dihydrate, flunixin meglumine, meloxicam, cloxacillin benzathine, carprofen, procaine HCL, and benzocaine. The company also has a range of finished products.
This year, CPhI is introducing a new feature—the Innovation Gallery—which aims to highlight innovative development across the pharmaceutical industry. Norbrook will be presenting one of the company’s flagship products, Closamectin Pour-On, which is the only cattle product in Europe that combines ivermectin and closantel for the simultaneous treatment of fluke as well as internal and external parasites.
Source: Norbrook
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
